FYB2: A Drug Target / Disease Biomarker (G199920)

Target Name: FYB2

NCBI ID: G199920

FYB2

FYB2: A Drug Target / Disease Biomarker

FYB2, also known as fyn-B2, is a protein that is expressed in the human placenta and is involved in the development and maintenance of fetal tissues. It is a key regulator of cell proliferation and has been identified as a potential drug target for several diseases.

The discovery of FYB2 as a drug target stems from a study by researchers at the University of California, San Diego, who identified that FYB2 was highly expressed in human placenta and that it was involved in the development and maintenance of fetal tissues. The researchers also found that FYB2 was a good candidate for a drug target because it was involved in multiple signaling pathways and was expressed in a variety of tissues, including the brain, heart, and liver.

Since the discovery of FYB2 as a potential drug target, there have been several studies conducted to further investigate its role in disease. For example, researchers at the University of California, San Diego have used RNA sequencing to identify potential targets for FYB2 in placenta and have found that there were several known proteins that were expressed in the placenta that were involved in cell proliferation and tissue development.

Another study by researchers at the University of California, San Diego, used a technique called live-cell imaging to show that FYB2 was involved in the development and maintenance of fetal tissues. The researchers used mice and found that when they deleted the FYB2 gene, the mice had difficulty with tissue development and had altered fetal behaviors.

In addition to its role in fetal tissue development, FYB2 has also been found to be involved in multiple signaling pathways that are important for cell proliferation and survival. For example, studies have shown that FYB2 was involved in the regulation of theNotch signaling pathway, which is important for cell survival and proliferation.

FYB2 has also been found to be involved in the regulation of the Wnt signaling pathway, which is important for cell growth and development. The Wnt signaling pathway is a well-established target for many diseases, including cancer, and researchers have identified several potential drug targets based on Wnt signaling.

FYB2 has also been found to be involved in the regulation of the TGF-β signaling pathway, which is important for cell growth and development. The TGF-β signaling pathway is a well-established target for many diseases, including cancer, and researchers have identified several potential drug targets based on TGF-β signaling.

In conclusion, FYB2 is a protein that is expressed in the human placenta and is involved in the development and maintenance of fetal tissues. Its role in multiple signaling pathways makes it a potential drug target for several diseases. Further research is needed to fully understand the role of FYB2 in disease and to develop effective treatments.

Protein Name: FYN Binding Protein 2

Functions: Adapter protein that plays a role in T-cell receptor (TCR)-mediated activation of signaling pathways. Required for T-cell activation and integrin-mediated T-cell adhesion in response to TCR stimulation (PubMed:27335501)

The "FYB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FYB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets